Worldwide Mantle Cell Lymphoma Treatment Industry to 2029 - by Mechanism of Action and Geography - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Mantle Cell Lymphoma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possess an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapy drug treatment and so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better drug efficacy and safety e.g. Zydelig, Gazyva, Abemaciclib and KTE-C19.

To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of mechanism of action are Bruton's Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.

To understand the performance of drugs employed for the treatment of mantle cell lymphoma in the regional segments their respective major countries has been considered in the segment.

Companies Mentioned

• Celgene Corporation Abbvie Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline Plc
• Amgen Inc.
• Gilead Sciences Inc. Johnson and Johnson
• F.Hoffman La Roche Ltd

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

Chapter 3. Mantle Cell Lymphoma Treatment Market: Dynamics and Future Outlook

3.1. Market Overview

3.2. Drivers

3.3. Challenges

3.4. Opportunities

3.5. Attractive Investment Proposition, by Geography

3.6. Top 3 Countries: Global Mantle Cell Lymphoma Treatment Market, 2019-2029 (US$ Mn)

3.7. Competitive Landscape: Global Mantle Cell Lymphoma Treatment Market, by Key Players, 2019-2029 (US$ Mn)

Chapter 4. Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2019 - 2029 (US$ Mn)

4.1. Overview

4.2. Attractive Investment Proposition: Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2020

4.3. Bruton's Tyrosine Kinase Blocker (Ibrutinib)

4.4. Angiogenesis Inhibitor (Lenalidomide)

4.5. CD20 Antigen Inhibitor (Rituximab)

4.6. mTOR Protein Inhibitor (Temsirolimus)

4.7. Proteasome Inhibitors (Bortezomib)

4.8. Phase III Drug

4.9. Tabular Representation of Phase II and I Drugs

Chapter 5. Global Mantle Cell Lymphoma Treatment Market, by Geography, 2019 - 2029 (US$ Mn)

5.1. Overview

5.2. North America Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029

5.3. Europe Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029

5.4. Asia Pacific Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029

5.5. Latin America Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029

5.6. Middle East & Africa Mantle Cell Lymphoma Treatment Market Analysis, 2019 - 2029

Chapter 6. Company Profiles

6.1. Abbvie, Inc.

6.2. Amgen, Inc.

6.3. Astellas Pharma, Inc.

6.4. Biogen, Inc.

6.5. Bayer AG

6.6. Bristol-Myers Squibb Company

6.7. Celgene Corporation

6.8. Eli Lilly and Company

6.9. GlaxoSmithKline Plc

6.10. Gilead Sciences, Inc.

6.11. Johnson and Johnson

6.12. F.Hoffman La Roche Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/5ujraa